Friend murine leukemia cells induced to undergo erythrocytic differentiation by dimethyl sulfoxide give rise to progeny resembling ortho-or polychromatic normoblasts, which usually do not complete the maturation process to yield forms analogous to erythrocytes. Treatment Cancer has been viewed by some investigators as a disease of abnormal differentiation in which the cellular processes that operate in normal development are repressed (1-6). If the expression of a malignant phenotype is epigenetically determined, it is conceivable that malignancy may be a reversible process (1, 2, 7). The Friend leukemia cell can be induced to differentiate along the erythrocytic pathway in vitro by dimethyl sulfoxide (Me2SO) (7) and a variety of other chemical agents (see refs. 8 and 9 for reviews and ref. 10); this property has made this murine erythroleukemia a popular model system to explore the factors that control the differentiation of immature malignant hematopoietic cells (8, 9, 11) . Fully differentiated Friend leukemia cells appear to be largely in the G1 phase of the cell cycle (12) and have limited proliferative capacity (13, 14); thus, their differentiation induced by Me2SO seems to represent an irreversible commitment to the erythroid pathway (13-16) that is characterized by the appearance of a number of biochemical and morphological changes similar to those observed during normal mouse erythropoiesis (8, 11). The majority of these cells mature to forms resembling polychromatic or orthochromatic normoblasts, and enucleation of differentiated Friend leukemia cells (corresponding to reticulocyte formation in normal erythropoiesis) occurs in less than 1% of the cell population (12). It has been reported, however, that enucleation can take place, but only in cells propagated in diffusion chambers (17). The present investigation demonstrates that Friend erythroleukemia cells can be induced to terminally differentiate to give rise to a high proportion of enucleated cells by the addition of cytochalasin B to cultures that have previously been induced to differentiate by treatment with Me2SO.
Cancer has been viewed by some investigators as a disease of abnormal differentiation in which the cellular processes that operate in normal development are repressed (1) (2) (3) (4) (5) (6) . If the expression of a malignant phenotype is epigenetically determined, it is conceivable that malignancy may be a reversible process (1, 2, 7) . The Friend leukemia cell can be induced to differentiate along the erythrocytic pathway in vitro by dimethyl sulfoxide (Me2SO) (7) and a variety of other chemical agents (see refs. 8 and 9 for reviews and ref. 10 ); this property has made this murine erythroleukemia a popular model system to explore the factors that control the differentiation of immature malignant hematopoietic cells (8, 9, 11) . Fully differentiated Friend leukemia cells appear to be largely in the G1 phase of the cell cycle (12) and have limited proliferative capacity (13, 14) ; thus, their differentiation induced by Me2SO seems to represent an irreversible commitment to the erythroid pathway (13) (14) (15) (16) that is characterized by the appearance of a number of biochemical and morphological changes similar to those observed during normal mouse erythropoiesis (8, 11) . The majority of these cells mature to forms resembling polychromatic or orthochromatic normoblasts, and enucleation of differentiated Friend leukemia cells (corresponding to reticulocyte formation in normal erythropoiesis) occurs in less than 1% of the cell population (12) . It has been reported, however, that enucleation can take place, but only in cells propagated in diffusion chambers (17) . The present investigation demonstrates that Friend erythroleukemia cells can be induced to terminally differentiate to give rise to a high proportion of enucleated cells by the addition of cytochalasin B to cultures that have previously been induced to differentiate by treatment with Me2SO .
MATERIALS AND METHODS
Me2SO, purchased from Fisher Scientific, was freshly distilled at 670C under reduced pressure and stored at -20'C in small vials that were thawed just prior to experiments. Cytochalasin B obtained from Aldrich Chemical was dissolved in absolute ethanol and added to cell cultures; final concentrations of ethanol did not exceed 0.1% and were not inhibitory to growth. Benzidine hydrochloride was purchased from Mallinckrodt, and fetal calf serum, Dulbecco's modified Eagle's medium, and antibiotics (streptomycin and penicillin) were from GIBCO.
Friend erythroleukemia 745 cells, kindly provided by N. Gabelman of Mount Sinai School of Medicine, were grown in polyethylene flasks containing Dulbecco's modified Eagle's medium supplemented with 10 or 15% calf serum, 100 ,ug of streptomycin per ml, and 100 international units of penicillin per ml at 370C in an incubator at 95% relative humidity with a 10% CO2 atmosphere. Cell growth was determined by using a Coulter model ZBI particle counter calibrated for the appropriate setting with known samples standardized with a hemocytometer.
Erythroid differentiation was measured by using 94-98% trypan blue-negative exponentially growing cell populations (8 X 72 hr after their transfer to drug-free medium, and by 108 hr of incubation, only 10-12% of the population were benzidine-positive; this phenomenon was attributed to dilution of benzidine-positive cells by replicating nondifferentiated cells present in Me2SO-pretreated cultures.
Preincubation of erythroleukemia cells with Me2SO for 88 hr prior to continuous exposure to cytochalasin B (1.0 or 2.5 ,ug/ml) resulted in the production of a significant proportion of pre-enucleated, enucleated, and multinucleated cells at 36 hr of reincubation (Fig. 3) . With and the number of enucleated elements increased markedly, becoming the dominant cellular form present in the population under all conditions of treatment at 108 hr. At this time, a mixed nucleus-free cell population was observed, consisting mainly of small benzidine-positive forms with a low proportion of large hemoglobin-containing elements. The simultaneous exposure of Me2SO-pretreated cells to both cytochalasin B and Me2SO increased the rate of formation of enucleated cells over that of cytochalasin B alone. Control and differentiated cultures reincubated in the absence of both Me2SO and cytochalasin B contained no more than 2% enucleated forms. Furthermore, no more than 1% pre-enucleated cells were present in control cultures, whereas the proportion of these cells ranged between 7 and 8% in differentiated cells transferred to medium containing Me2SO (data not shown). Cytological evidence for the formation of the various cellular types is shown in Fig. 4 . Control undifferentiated cells were not enucleated by treatment with cytochalasin B alone, but instead gave rise to cultures consisting largely of basophilic multinucleated cells as described earlier (26) (Fig. 4E) . The multinucleated cells present in cultures treated with both cytochalasin B and Me2SO were large eosinophilic forms containing highly pycnotic nuclei. Alterations in shape and morphology of Friend leukemia cells occurred during the process of enucleation; thus, whereas control nucleated cells had a high ratio of nucleus to cytoplasm (Fig. 4A) , cells induced to differentiate by treatment with Me2SO prior to exposure to cytochalasin B for 24 hr were smaller and had highly pycnotic eccentrically located nuclei (pre-enucleated cells) (Fig. 4B) . Further progression of these cells induced by longer periods of exposure to the antibiotic led to the formation of nucleus-free cells with occasional surface irregularities (Fig. 4 C and D) . On occasion, cells with partially extruded nuclei were observed. These findings suggest that differentiated Friend leukemia cells treated with cytochalasin B are capable of extruding their nuclei through the plasma membrane in a fashion comparable to that occurring during the transition of a normoblast to a reticulocyte (27) . Measure enucleate upon treatment with cytochalasin B. However, mature cultures containing a high proportion of benzidine-positive cells gave rise to a large number of enucleated forms.
We observed recently that addition of 0.1 mM hemin, an inducer of erythroid cell differentiation (28) , to cultures of Me2SO-treated Friend leukemia cells followed by exposure to cytochalasin B yielded a high proportion (90%) of hemoglobin-containing cells. These nucleus-free forms appeared to be morphologically superior to cells induced to enucleate by cy- (21, (23) (24) (25) . That nuclear extrusion occurs only in differentiated cells was suggested by the finding that multinucleated cells were formed in populations of Friend leukemia cells treated for only a brief period of time with Me2SO before exposure to cytochalasin B, whereas cells receiving prolonged treatment with Me2SO prior to exposure to the antibiotic underwent enucleation by a process resembling that of the conversion of normoblasts into reticulocytes during normal erythropoiesis (27) . Because nondifferentiated erythroleukemia cells did not extrude their nuclei upon treatment with cytochalasin B, whereas differentiated cells did, metabolic changes must have occurred during the maturation process that rendered the differentiated cells capable of nuclear extrusion after the chemical "push" produced by cytochalasin B.
Conversion of differentiated cells to enucleated forms does not occur in a synchronous fashion, presumably because the cells' degree of maturity varied at the time of exposure to cytochalasin B. Cytochalasin B may cause the nuclear extrusion in differentiated cells by interactions at the level of the plasma membrane by altering cell surface integrity, possibly as a result of interaction with membrane lipids (29) . Evidence also exists to indicate that cytochalasin B affects the organization of actin and the differentiation of rat lens epithelial cells in vitro (30) .
Information obtained from the present system may be valuable for exploring the mechanisms involved both in normal erythroid maturation and in abnormal differentiation of tissues arrested at particular stages of development during the transition to the neoplastic state. Two recent reports on the chemical differentiation of human (31) and mouse (32) myeloid leukemia further support the concept that maturation of some tumors may be an alternate approach to existing cancer therapy.
